Neurogene
NGNE
52 hedge funds and large institutions have $12M invested in Neurogene in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 21 reducing their positions, and 16 closing their positions.
0.25% less ownership
Funds ownership: 2.45% → 2.2% (-0.25%)
17% less funds holding
Funds holding: 63 → 52 (-11)
44% less capital invested
Capital invested by funds: $21.4M → $12M (-$9.43M)
67% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 21
69% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$640K |
| 2 |
PFMU
Privium Fund Management (UK)
London,
United Kingdom
|
+$120K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$85.5K |
| 4 |
Two Sigma Investments
New York
|
+$31.3K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$21.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$805K |
| 2 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$805K |
| 3 |
Millennium Management
New York
|
-$429K |
| 4 |
D.E. Shaw & Co
New York
|
-$202K |
| 5 |
Renaissance Technologies
New York
|
-$176K |
NGNE Hedge Fund Activity: Q3 2022 in Review
52 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Neurogene (NGNE) for Q3 2022, worth a combined $12M — down 44% from $21.4M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of NGNE and 5 opened new positions — a net loss of 11 holders — while 21 trimmed existing stakes and 7 added.
The largest buyer was Point72 Asset Management, adding an estimated $640K. The largest seller was Candriam SCA, exiting entirely with an estimated $805K sold.
- 52 institutional investors held Neurogene (NGNE) as of Q3 2022, down from 63 in Q2 2022.
- Funds reported $12M of Neurogene stock for Q3 2022, down 44% quarter-over-quarter.
- 5 funds opened new Neurogene positions in Q3 2022 and 16 closed out, a net change of -11 holders.
- The largest Neurogene buyer in Q3 2022 was Point72 Asset Management, an estimated $640K added.
- The largest Neurogene seller in Q3 2022 was Candriam SCA, an estimated $805K sold.
Based on aggregated 13F filings for Q3 2022.